(SLE)
BEPRANEMAB(INNC)
IMMUNOGLOBULIN G4-KAPPA, ANTI-[HOMO SAPIENS MAPT (MICROTUBULEASSOCIATED PROTEIN TAU, TAU)], HUMANIZED MONOCLONAL ANTIBODY; GAMMA4 HEAVY CHAIN HUMANIZED (1-445) [VH (HOMO SAPIENS IGHV4-4*08 (83.5%) -(IGHD) -IGHJ3*01 (93.3%)) CDR-IMGT [8.7.12] (26-33.51-57.96-107) (1-118)-HOMO SAPIENS IGHG4*01, G4V5 H P10 (CH1 (119-216), HINGE 1-12 S10>P (226) (217-228), CH2 (229-338), CH3 (339-443), CHS (444-445)) (119-445)], (132- 219')-DISULFIDE WITH KAPPA LIGHT CHAIN HUMANIZED (1'-219') [V-KAPPA (HOMO SAPIENS IGKV2-29*02 (90.0%) -IGKJ2*01 (100%)) CDRIMGT [11.3.9] (27-37.55-57.94-102) (1'-112') -HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (158), V101 (196) (113'-219')]; DIMER (224-224":227-227")-BISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, GLYCOFORM ALFA. PROPOSED INN: LIST 122(WHO)
BEPRANEMABUM(INN)